Open Access Open Access  Restricted Access Subscription Access

Multiple-criteria assessment of patient access in hematology in Central Eastern Europe

Nóra Páll-Czippán, Márk Péter Molnár, Dávid Dankó

Abstract


Background: Although patient access has been captured and operationalized via several indicators, such indicators tend to restrict the concept of patient access to the length of the reimbursement process and delays in treatment decisions.

Objective: The main goal of this study was to identify and assess the differences in patient access in Central Eastern European (CEE) cancer care (with a focus on chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) in 8 individual CEE countries.

Method: We developed a comprehensive, multiple-criteria decision analysis framework that reflects the entire care delivery pathway in CLL and MM.

Results: Even though CEE countries have been gradually adopting international clinical recommendations, many differences persist with respect to how they provide access to public funding. Robust registries with reliable data are rarely available. Patient advocacy groups (PAGs) are present and active in promoting person-centered healthcare in all countries but their involvement in decision-making is usually informal.

Conclusion: Our research revealed that in order to further improve patient outcomes at systemic level, it is important to better understand country-specific nuances and development needs.

Keywords


Chronic lymphocytic leukemia, gap analysis, hematology, multiple-criteria decision analysis, multiple myeloma, patient access, patient advocacy groups, patient/disease registries, patient organisations, person-centered healthcare

Full Text:

PDF

References


Health Consumer Powerhouse. Euro Health Consumer Index 2017. (2018). [cited 2019 July 23]; Available from: https://healthpowerhouse.com/media/EHCI-2017/EHCI-2017-report.pdf.

Vrdoljak, E., Bodoky, G., Jassem, J. et al. (2016). Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. Oncologist 21 (10) 1183-1190.

European Federation of Pharmaceutical Industries and Associations (EFPIA). (2018). EFPIA Market Access Delays Analysis. [cited 2019 July 23]; Available from: https://www.efpia.eu/media/412416/market-access-delays-2017-final-140318.pdf.

Egészségügyi Szakmai Kollégium Tagozatai és Tanácsai. (2019). National clinical guidelines database for Hungary. [cited 2019 July 25]; Available from: https://kollegium.aeek.hu/Iranyelvek/Index?AspxAutoDetectCookieSupport=1.

Združenje Hematologov Slovenije. (2019). National clinical guidelines for Slovenia.[cited 2019 July 25]; Available from: http://www.hematologija.org/si/en/guidelines/.

Haute Autorité de Santé and Institut National du Cancer. (2011). Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique Leucémie lymphoïde chronique. [cited 2019 July]; 25]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2011-09/ald_30__gm_llc_web_2vf.pdf.

Robak, T., Hus, I., Giannopoulos, K., Błoński, J., Jamroziak, K., Roliński, J., Smolewski, P. & Wołowiec, D. (2016). Diagnostic and therapeutic recommendations of the Polish Society of Hematology and Transfusion Medicine and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2016. Acta Haematologica Polonica 47 (3) 169-183.

Lymfómová skupina Slovenska. (2018). Stratégia liečby malígnych lymfómov. [cited 2019 July 25]; Available from: http://lysk.sk/wp-content/uploads/2018/11/strategia-liecby.pdf.

National Council on Prices and Reimbursement of Medicinal Products. (2018). Pharmacotherapeutic guidances. [cited 2019 July 25]; Available from: https://ncpr.bg/images/farmako-terapevtichni/FTR_Hematology_2018_250418__JT_29.05.2018-J51.pdf.

Zákon č. 363/2011 Z. z. o rozsahu a podmienkach úhrady liekov, zdravotníckych pomôcok a dietetických potravín na základe verejného zdravotného poistenia a o zmene a doplnení niektorých zákonov. [cited 2019 Aug 28]; Available from: https://www.zakonypreludi.sk/zz/2011-363.

Regulation 10/2011 on the term and rules for treatment with medicinal product not licensed in Bulgaria [cited 2019 Aug 28]; Available from: https://www.tma-bulgaria.com/en/translations-of-pharma-legislation-in-english.html.

Ministerstwo Zdrowia. (2019). Reimbursement List for Poland. [cited 2019 May 1]; Available from: https://www.gov.pl/web/zdrowie/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych.

State Institute for Drug Control. (2019). Reimbursement List for Czech Republic. [cited 2019 May 1]; Available from: http://www.sukl.eu/modules/medication/search.php.

Ministerstvo Zdravotníctva Slovenskej Republiky. (2019). Reimbursement List for Slovakia. [cited 2019 May 1]; Available from: https://www.health.gov.sk/?zoznam-kategorizovanych-liekov.

National Health Insurance Fund. (2019). Reimbursement List for Hungary. [cited 2019 May 1]; Available from: http://www.neak.gov.hu/felso_menu/szakmai_oldalak/gyogyszer_segedeszkoz_gyogyfurdo_tamogatas/egeszsegugyi_vallalkozasoknak/pupha/Vegleges_PUPHA.html.

Slovenian Health Insurance Fund. (2019). Reimbursement List for Slovenia. [cited 2019 May 1]; Available from: http://www.zzzs.si/ZZZS/info/egradiva.nsf/sprem_listB?OpenView&count=1000.

National Council on Prices and Reimbursement of Medicinal Products. (2019). Reimbursement List for Bulgaria. [cited 2019 May 1]; Available from: http://portal.ncpr.bg/registers/pages/register/list-medicament.xhtml.

Ministerul Sanatatii. (2019). Reimbursement List for Romania. [cited 2019 May 1]; Available from: http://www.cnas.ro/media/pageFiles/Lista%20medicamentelor%20SublistaC%20Sectiunea%20C2-01.01.2019.pdf.

Kassenartzliche Bundesvereinigung. (2019). Reimbursement List for Germany. [cited 2019 May 1]; Available from: https://www.kbv.de/html/online-ebm.php.

Hauptverband der österreichischen Sozialversicherungsträger. (2019). Reimbursement List for Austria. [cited 2019 May 1]; Available from: http://www.hauptverband.at/cdscontent/load?contentid=10008.637165&version=1515485239.

Ministere des Affaires sociales et de la Santé. (2019). Reimbursement List for France. [cited 2019 May 1]; Available from: http://medicprix.sante.gouv.fr/medicprix/welcome.do.

Croatian Health Insurance Fund. (2019). Novi lijekovi na listama lijekova. [cited 2019 July 25]; Available from: https://www.hzzo.hr/novi-lijekovi-na-listama-lijekova-3/.

Czech Leukemia Study Group for Life. (2019). Databáze pacientů s chronickou lymfocytární leukemií (CLL). [cited 2019 July 26]; Available from: http://www.leukemia-cell.org/index.php?pg=cllear--informace-o-projektu.

Czech Myeloma Group. (2019). Registry of Monoclonal Gammopathies. [cited 2019 July 26]; Available from: https://rmg.healthregistry.org/index.php.




DOI: http://dx.doi.org/10.5750/ejpch.v7i4.1778

Refbacks

  • There are currently no refbacks.